{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:29:13Z","timestamp":1783384153593,"version":"3.54.6"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82430010"],"award-info":[{"award-number":["82430010"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015406","name":"Tianjin Science and Technology Commission","doi-asserted-by":"publisher","award":["24ZXZSSS00230"],"award-info":[{"award-number":["24ZXZSSS00230"]}],"id":[{"id":"10.13039\/501100015406","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010041","name":"Tianjin Municipal Science and Technology Committee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2023-I2M-2-007"],"award-info":[{"award-number":["2023-I2M-2-007"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2023ZD0500803"],"award-info":[{"award-number":["2023ZD0500803"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.eclinm.2025.103459","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T09:15:05Z","timestamp":1755767705000},"page":"103459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study)"],"prefix":"10.1016","volume":"87","author":[{"given":"Yunfei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4109-2602","authenticated-orcid":false,"given":"Jinsong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7493-8347","authenticated-orcid":false,"given":"Jie","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7769-7377","authenticated-orcid":false,"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.eclinm.2025.103459_bib1","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/bloodadvances.2020001446","article-title":"Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP: a nationwide study in Japan","volume":"4","author":"Hato","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103459_bib2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-023-01401-z","article-title":"How we treat primary immune thrombocytopenia in adults","volume":"16","author":"Liu","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103459_bib3","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1016\/S2352-3026(24)00139-X","article-title":"Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"11","author":"Hu","year":"2024","journal-title":"Lancet Haematol"},{"issue":"15","key":"10.1016\/j.eclinm.2025.103459_bib4","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103459_bib5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.27554","article-title":"Clinical use of eltrombopag and avatrombopag in pediatric ITP in China: a real-world multicenter retrospective cohort study","volume":"100","author":"Liu","year":"2024","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1016\/j.eclinm.2025.103459_bib6","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1182\/blood-2013-07-514398","article-title":"A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia","volume":"123","author":"Bussel","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103459_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-021-01047-9","article-title":"A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"22","key":"10.1016\/j.eclinm.2025.103459_bib8","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.eclinm.2025.103459_bib9","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1097\/CM9.0000000000002346","article-title":"Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study","volume":"135","author":"Cai","year":"2022","journal-title":"Chin Med J (Engl)"},{"issue":"SUPPL 2","key":"10.1016\/j.eclinm.2025.103459_bib10","first-page":"547","article-title":"Eltrombopag plus rhtpo versus eltrombopag for itp during the covid-19 pandemic (elaborate-19). 26th Congress of the European Hematology Association","volume":"5","author":"An","year":"2021"},{"issue":"13","key":"10.1016\/j.eclinm.2025.103459_bib11","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1182\/bloodadvances.2024013317","article-title":"Immune thrombocytopenia guidelines get an annual checkup","volume":"8","author":"Gallo","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103459_bib12","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1111\/bjh.19761","article-title":"Efficacy and safety of recombinant human thrombopoietin for the treatment of chronic primary immune thrombocytopenia in children and adolescents: a multicentre, randomized, double-blind, placebo-controlled phase III trial","volume":"205","author":"Ma","year":"2024","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103459_bib13","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jtct.2024.02.023","article-title":"Recombinant human thrombopoietin promotes platelet engraftment in severe aplastic anemia patients following treatment with haploid hematopoietic stem cell transplantation using modified post-transplantation cyclophosphamide","volume":"30","author":"Fu","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"16","key":"10.1016\/j.eclinm.2025.103459_bib14","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2003.08.003","article-title":"Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia","volume":"21","author":"Vadhan-Raj","year":"2003","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103459_bib15","first-page":"617","article-title":"[Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020)]","volume":"41","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103459_bib16","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/bjh.17808","article-title":"A multicentre double-blind, double-dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients","volume":"195","author":"Mei","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103459_bib17","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2023.2271568","article-title":"Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia","volume":"34","author":"Wang","year":"2023","journal-title":"Platelets"},{"issue":"9763","key":"10.1016\/j.eclinm.2025.103459_bib18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103459_bib19","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1186\/s12884-023-06134-y","article-title":"Recombinant human thrombopoietin therapy for primary immune thrombocytopenia in pregnancy: a retrospective comparative cohort study","volume":"23","author":"Lin","year":"2023","journal-title":"BMC Pregnancy Childbirth"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103459_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/bjh.14380","article-title":"Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia","volume":"176","author":"Yang","year":"2017","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.eclinm.2025.103459_bib21","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","article-title":"Romiplostim or standard of care in patients with immune thrombocytopenia","volume":"363","author":"Kuter","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103459_bib22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1083\/jcb.201304054","article-title":"The incredible journey: from megakaryocyte development to platelet formation","volume":"201","author":"Machlus","year":"2013","journal-title":"J Cell Biol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103459_bib23","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103459_bib24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bjh.17825","article-title":"TPO versus TPO: the good, the bad, and the to be determined","volume":"195","author":"Lee","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103459_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5045\/br.2015.50.1.19","article-title":"Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia","volume":"50","author":"Kim","year":"2015","journal-title":"Blood Res"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103459_bib26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/2042098618769587","article-title":"Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety","volume":"9","author":"Gonzalez-Porras","year":"2018","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103459_bib27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2125.2011.03972.x","article-title":"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers","volume":"72","author":"Allred","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103459_bib28","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood-2014-06-581868","article-title":"A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP","volume":"125","author":"Zhou","year":"2015","journal-title":"Blood"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:38:50Z","timestamp":1758616730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025003918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":28,"alternative-id":["S2589537025003918"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103459","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study)","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103459"}}